USS Investment Management Ltd Decreases Position in Agilent Technologies, Inc. $A

Key Points

• USS Investment Management Ltd has reduced its stake in Agilent Technologies by 4.8%, owning 102,370 shares worth approximately $11.97 million after selling 5,170 shares in the first quarter.
• Agilent Technologies reported a significant 10.1% year-over-year revenue increase to $1.74 billion and also met consensus estimates for earnings per share at $1.37.
• Several analysts have recently adjusted their price targets for Agilent, with a consensus rating of "Moderate Buy" and an average target price of $139.25.

USS Investment Management Ltd decreased its holdings in shares of Agilent Technologies, Inc. (NYSE:A - Free Report) by 4.8% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 102,370 shares of the medical research company's stock after selling 5,170 shares during the quarter. USS Investment Management Ltd's holdings in Agilent Technologies were worth $11,972,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in A. Brighton Jones LLC lifted its stake in Agilent Technologies by 6.1% during the fourth quarter. Brighton Jones LLC now owns 4,663 shares of the medical research company's stock worth $626,000 after purchasing an additional 270 shares during the last quarter. Captrust Financial Advisors lifted its stake in Agilent Technologies by 8.5% during the fourth quarter. Captrust Financial Advisors now owns 22,578 shares of the medical research company's stock worth $3,033,000 after purchasing an additional 1,769 shares during the last quarter. D. E. Shaw & Co. Inc. lifted its stake in Agilent Technologies by 183.7% during the fourth quarter. D. E. Shaw & Co. Inc. now owns 38,203 shares of the medical research company's stock worth $5,132,000 after purchasing an additional 24,739 shares during the last quarter. Ensign Peak Advisors Inc lifted its stake in Agilent Technologies by 370.0% during the fourth quarter. Ensign Peak Advisors Inc now owns 124,575 shares of the medical research company's stock worth $16,735,000 after purchasing an additional 98,068 shares during the last quarter. Finally, Focus Partners Wealth lifted its stake in Agilent Technologies by 0.4% during the fourth quarter. Focus Partners Wealth now owns 101,225 shares of the medical research company's stock worth $13,732,000 after purchasing an additional 444 shares during the last quarter.

Insider Activity at Agilent Technologies

In other news, CEO Padraig Mcdonnell sold 1,508 shares of the company's stock in a transaction that occurred on Tuesday, July 1st. The stock was sold at an average price of $117.44, for a total transaction of $177,099.52. Following the completion of the sale, the chief executive officer owned 37,448 shares in the company, valued at $4,397,893.12. This represents a 3.87% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Agilent Technologies Price Performance

Agilent Technologies stock opened at $128.69 on Monday. Agilent Technologies, Inc. has a 12 month low of $96.43 and a 12 month high of $153.84. The company has a debt-to-equity ratio of 0.53, a current ratio of 2.25 and a quick ratio of 1.71. The business has a 50 day simple moving average of $119.22 and a 200-day simple moving average of $116.05. The stock has a market capitalization of $36.48 billion, a PE ratio of 30.21, a price-to-earnings-growth ratio of 4.00 and a beta of 1.24.

Agilent Technologies (NYSE:A - Get Free Report) last released its quarterly earnings results on Wednesday, August 27th. The medical research company reported $1.37 EPS for the quarter, hitting the consensus estimate of $1.37. Agilent Technologies had a return on equity of 25.51% and a net margin of 17.97%.The business had revenue of $1.74 billion during the quarter, compared to analysts' expectations of $1.67 billion. During the same quarter in the prior year, the business earned $1.32 earnings per share. The company's quarterly revenue was up 10.1% compared to the same quarter last year. Agilent Technologies has set its FY 2025 guidance at 5.560-5.590 EPS. Q4 2025 guidance at 1.570-1.600 EPS. Equities analysts predict that Agilent Technologies, Inc. will post 5.58 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on A shares. Leerink Partners boosted their target price on Agilent Technologies to $135.00 and gave the stock a "buy" rating in a research note on Friday, May 30th. Evercore ISI reduced their price objective on Agilent Technologies from $130.00 to $128.00 and set an "in-line" rating for the company in a research note on Thursday, August 28th. Robert W. Baird boosted their price objective on Agilent Technologies from $141.00 to $142.00 and gave the company an "outperform" rating in a research note on Thursday, August 28th. Wall Street Zen cut Agilent Technologies from a "buy" rating to a "hold" rating in a research note on Friday. Finally, Wells Fargo & Company boosted their price objective on Agilent Technologies from $135.00 to $140.00 and gave the company an "overweight" rating in a research note on Thursday, August 28th. Six research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company's stock. According to data from MarketBeat.com, Agilent Technologies presently has a consensus rating of "Moderate Buy" and an average target price of $139.25.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.